evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 20%GRADE not reported 0 · 0%Very low 3 · 60%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

Pazopanib plus lapatinib vs lapatinib

Specific adverse events: haemorrhage · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).

1 finding from 1 review

Cediranib plus chemotherapy vs placebo plus chemotherapy

Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).

1 finding from 1 review

Bevacizumab plus chemotherapy vs chemotherapy alone

Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer

Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).

1 finding from 1 review